Log-rank analysis confirmed that GBM patients expressing “Very Low” levels of ANXA2 mRNA (< 25° percentile) survived significantly longer in terms of OS (Figure 1G, 1H and Table 1) and PFS (Table 1 and Supplementary Figure S3), independently from the molecular subtype to which they were assigned according to the Verhaak classification [29] (Supplementary Figure S4). The gene discussed is ANXA2; the disease is glioblastoma.